Clinical Edge Journal Scan

Lenvatinib combination therapy vs monotherapy against HCC: Real-world results


 

Key clinical point: Lenvatinib-based combination therapies are associated with a significantly longer progression-free survival (PFS) and better objective response (OR) than lenvatinib monotherapy in patients with hepatocellular carcinoma (HCC).

Major finding: Lenvatinib combination therapy vs monotherapy was associated with a significantly longer PFS (Response Evaluation Criteria in Solid Tumours [RECIST] v1.1: 7.77 vs 4.43 months; P = .045; modified RECIST [mRECIST]: 6.97 vs 5.27 months; P = .067) and a higher OR rate (RECIST v1.1: 37% vs 5%; P < .001; mRECIST: 53% vs 11%; P < .001) but no significant overall survival benefit ( P = .71).

Study details: Findings are from a retrospective study that included 215 patients with HCC who received lenvatinib-based therapies.

Disclosures: This study was funded by the National Key R&D Program of China and National Natural Science Foundation of China. The authors declared no conflicts of interest.

Source: Chen J et al. The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study. J Cancer Res Clin Oncol. 2022 (Jun 25). Doi: 10.1007/s00432-022-04082-2

Recommended Reading

HCC with Child-Pugh B cirrhosis: Nivolumab a promising first-line systemic treatment option
Federal Practitioner
Atezolizumab plus bevacizumab offers a better prognosis than lenvatinib in unresectable HCC
Federal Practitioner
Unresectable HCC: Differential efficacy of atezolizumab plus bevacizumab according to hepatic function grade
Federal Practitioner
SBRT plus TACE better than monotherapy in HCC with portal vein tumor thrombus
Federal Practitioner
Commentary: Locoregional Treatments for HCC, July 2022
Federal Practitioner
Advanced HCC: First-line cabozantinib+atezolizumab in select patients shows promise but requires further study
Federal Practitioner
First-line pembrolizumab: A promising therapeutic option in advanced HCC
Federal Practitioner
RFA and TACE: Equally effective bridging treatments in HCC patients awaiting liver transplant
Federal Practitioner
Sustained virologic response beneficial in patients with HCV-related HCC receiving nonsurgical management
Federal Practitioner
Advanced HCC: Radiotherapy+anti-PD1 a better therapeutic regimen than TACE+sorafenib
Federal Practitioner